Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392957 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT07392957 is a Phase 1 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 54 participants.
The verdict
NCT07392957, a Phase 1 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma. CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment
Interventions
- DRUG CTX-009
- DRUG CTX-471
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-06-16 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392957
The ClinicalTrials.gov registry entry for NCT07392957 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CTX-009 is the first listed.
NCT07392957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07392957 about?
NCT07392957 is a clinical study titled "Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma". This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or i...
What is the current status of trial NCT07392957?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2026-06-16. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT07392957?
The interventions under investigation include: CTX-009 (DRUG), CTX-471 (DRUG).
Who is sponsoring clinical trial NCT07392957?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.